BMI and Comorbidity Thresholds The FDA's approved labeling for semaglutide 2.4 mg (Wegovy) requires a BMI 30, or a BMI 27 with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia [3]
Xultophy 100/3.6 (insulin degludec and liraglutide injection) [package insert]
The Microdose GLP-1 Protocol, for example, uses lower initial concentrations designed to minimize gastrointestinal side effects while building tolerance
This broad-based easing is a global theme
Atropine: Clinical Pharmacology and Emergency Application
Notably, the PROTACs that have advanced into clinical studies are, in most cases, still based on this small-molecule design paradigm, rather than on macromolecular or biomacromolecular carrier systems